European Partnership on One Health Antimicrobial Resistance 2027
The Health Research Board (HRB), in collaboration with Research Ireland and the Department of Agriculture, Food and the Marine (DAFM), is participating in the One Health Antimicrobial Resistance (OHAMR) Joint Transnational Call 2027. We aim to support Irish researchers to engage in transnational collaborative research in the field of antimicrobial resistance (AMR) with a One Health approach under the call entitled “Understand, Model and Stop AMR Transmission”.
The vision of European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) is to reduce the burden of antimicrobial resistance.
This EUP OHAMR call will focus on preventing the emergence and spread of AMR. Current measures to decrease and control the emergence and spread of AMR and recent technical advances are still insufficient to reduce the burden of AMR. More knowledge on transmission dynamics is needed. In the coming years, novel and/or improved measures need to be developed to control AMR, based on a better understanding of the mechanisms driving emergence, evolution, selection, persistence, and transmission of AMR, in and between different One Health (OH) sectors.
A webinar will take place on 25 November 2026 (12:30 – 14:30 GMT) to present the OHAMR JTC2027 and the partner search tool. All interested applicants are invited to register for the webinar.
For further information, including call and guidance documents, please visit the OHAMR JTC2027 webpage.
Guidance
Closing Date: 01-02-2027
Duration: 36 months
Funding: €330,000 - €405,000 direct costs
Decision expected: October/November 2027
International / EU partners needed
Details of this scheme::
A brief summary of the call is provided below along with additional information on eligibility for applicants requesting funding from HRB. Please refer to the OHAMR JTC2027 webpage for all call documents.
Call Scope:
Proposals submitted under this call must address one of three designated topics. Please note that each of the Irish funding organisations participating in this call (HRB, Research Ireland and DAFM) has specific requirements in relation to the scientific scope.
The HRB will fund applications in all One Health settings under Topic 1 and Topic 3, provided the research focus clearly demonstrates its relevance and connection to Human Health. The HRB will not fund applications under Topic 2.
Research Ireland will fund applications in all One Health settings under Topics 1, 2 and 3. DAFM will fund applications under Topic 2, targeting the Environment, Animal or Plant settings.
Topic 1: Model AMR transmission dynamics to predict the risk of AMR emergence and spread to support decision-making of public authorities.
Proposals addressing this topic should develop AMR transmission models at the global scale to predict the emergence and spread of antibiotic and/or antifungal resistance (within One-Health settings or between different One-Health settings) to support the public authorities in taking evidence-based decisions to curb AMR transmission and spread. The models proposed should consider the contribution of the anthropogenic activities (such as agriculture, travels, trade, large gatherings, migration, war, etc) and/or societal properties (e.g. behavioural aspects of the population, population distribution) and climate change (heatwave, floods, etc) in order to identify points of intervention. Documented and coordinated collection, use and/or re-use of existing data and quality assessments are expected.
Topic 2: Understand and characterise the role of host commensal micro-organisms (including fungi) in AMR dynamics and develop solutions aiming at selective decolonising of resistant organisms in the host (human and animals) to prevent transmission.
Commensal micro-organisms in humans and animals can act as reservoirs of resistance genes, which can be transferred to pathogens. The purpose of this topic is to better understand the role of commensal organisms in the spread of AMR, and propose solutions to prevent AMR transmission.
Topic 3: Develop or improve tools and methods to reduce resistant bacteria, fungi, and resistance genes in environmental hotspots, and investigate the impact of these tools and methods on AMR transmission.
Hotspots are where resistant bacteria, fungi, and resistant genes are present in large quantity for example: wastewater treatment plants, hospital pipelines, effluent of antibiotic and antifungal manufacturing production sites and manure. Proposals addressing this topic should identify, develop, improve and/or test innovative solutions facilitating the decontamination of the environmental hotspots (including, but not limited to the sites mentioned above) and demonstrate the impact on AMR transmission and on human health (excluding infection prevention and control measures). Proposals addressing this topic must consider at least two One Health settings (Human, Environment).
Please note that for all call topics:
Proposals should consider how the expected results will impact the risk of resistance in other One Health settings, and how the results could be extended to additional One Health settings.
Proposals should explain their feasibility by outlining realistic objectives, practical methodologies, and achievable timelines (e.g.: workplan, risk identification, allocation of resources, capacity of the consortium to conduct the work, business plan if the proposal envisages commercial component, etc).
Proposals must clearly demonstrate the potential health, social and/or economic impact(s) of the expected results. In particular, the proposals should explain how the uptake of the expected project results by the society/end-users/next actors will be facilitated (Pathway to impact).
Proposals should clearly demonstrate the unique contribution of each partner (i.e. expertise, resources). In addition, the proposals should demonstrate the added value of transnational collaboration: sharing of expertise and resources (models, databases…), harmonization of data, access to innovative technologies, etc.
Participation of the private sector (start-up, SMEs, industry) in the consortium is encouraged for all call topics, if appropriate (and in accordance to national/regional funding eligibility rules).
Proposals submitted to this call should not present overlap with proposals by the same consortium submitted to/granted by other Horizon Europe or EU4Health calls or with projects previously funded by JPIAMR. In their full proposal, applicants will be asked to identify potential related projects and describe how their proposal does not overlap with, but possibly complements, a related EU project (including projects funded by other European Partnerships, projects submitted to external calls, as well as research activities funded internally).
Clinical trials cannot be funded in this call.
Irish Partner(s) are not eligible for HRB funding for:
Proposals addressing Topic 2, as well as proposals addressing Topic 1 or Topic 3 that do not clearly demonstrate their relevance and connection to Human Health;
Proposals involving basic biomedical research;[1]
Research intended to create human embryos solely for the purposes of research or for the purposes of stem cell procurement, including by means of somatic cell nuclear transfer;
Applications from individuals applying for, holding, or employed under funding received from the tobacco industry;[2]
Applications from individuals applying for, holding, or employed under funding received from the alcohol industry and related actors.[3]
Major changes since JPIAMR:
We have introduced a sign-off process for Host Institutions (HIs) to align with other HRB schemes. Each project partner that is requesting funding from HRB needs a HI sign off. Please consult the ‘Host Institution sign off’ section below for additional information.
[1] Basic biomedical research refers to very early stage, fundamental research. HRB permits pre-clinical research within this call on the understanding that pre-clinical studies represent an important stage of research that occurs before testing in humans to find out if a drug, treatment or procedure is likely to be useful. Work with animal models and human samples is eligible under this call.
[2] Any company, entity, or organisation involved in the development, production, promotion, marketing, or sale of tobacco in any country of the world. The term also includes any companies that are a subsidiary or a holding company or affiliate of the above. This also includes e-cigarette companies and non-tobacco related companies which are fully or partially owned by the tobacco industry.
[3] Including social aspects/public relations organisations (SAPROs) funded by alcohol companies or trade associations in which such companies are members.
Funding Available, Duration and Start Date::
Projects are expected to start between December 2027 and April 2028. Awards will have a duration of up to 36 months.
Please note: Funding awarded under this call is co-funded by the European Union under Horizon Europe. Applicants requesting funds to the HRB are responsible for complying with all applicable EU rules, regulations and guidance associated with this funding, in addition to HRB’s terms and conditions. Detailed budgets must be provided at full-proposal stage and must comply with all applicable EU (Horizon Europe) and HRB funding rules. Eligible costs and funding rules may vary between the respective national/regional funding organisations (see the call text). Further information regarding eligible costs will be provided prior to the full proposal stage.
For applicants based in Ireland, the HRB will provide funding for projects up to a maximum of €330,000 direct costs per award. Additional funding of up to €75,000 direct costs will be made available for coordination activities (cannot be used to cover equipment and consumables) bringing the total to €405,000 direct costs for coordinators. The maximum total award, including overhead contribution, will be €430,000, for a partner and €530,000 for applicants who take on the role of coordinator.
Funding available is inclusive of overheads and pension contributions.
The HRB plans to commit up to €530,000 to the OHAMR JTC2027 awards. Quality permitting, a minimum of one award will be funded.
The award will offer research-related costs for:
Personnel: (i) Salary-related costs in line with the most recent IUA (or other most applicable) scale for funded personnel; (ii) Salary related costs for Lead Applicants in contract positions up to a maximum of 0.5 FTE protected time for research funded by HRB; (iii) Postgraduate stipends and fees (Master’s students only).
Direct running costs (including travel, mobility costs, patient-related costs, and costs to support interventional studies)
PPI costs
Small equipment costs (not to exceed €10k)
Research Data Management and Sharing Costs: Data stewardship costs (e.g. service/fees from data steward, access to secondary data, costs of making data FAIR, etc.)
Dissemination and knowledge exchange activities (including open access scientific publications, dissemination-related travel, etc.)
Sub-contracting costs for the provision of a service can be covered up to a maximum of 20% of direct costs. This would need to conform with the Host Institution, National and EU (Horizon Europe) procurement rules. These costs should be necessary, specific to the project and proportionate and they should normally constitute only a limited part of the project.
Overheads contribution (25% TDMC for desk-based work; 30% TDMC for lab/clinical-based work. TDMC (total direct modified costs) is the total direct costs excluding equipment, student fees and subcontracting.
Please note that further information regarding eligible costs will be provided at a later stage, before submission of full proposals.
Note: The OHAMR JTC2027 award will not fund PhD stipends and fees, nor the salary and related costs of tenured academic staff within research institutions (including buy-out from teaching time etc.). The latter does not apply to contract researchers, as outlined above.
The budget requested and the award duration must reflect the scale and nature of the proposed research.
Funded Personnel
Alignment between personnel requested and the proposed project should be demonstrated. Roles and responsibilities of funded personnel must be differentiated and clear.
This scheme is not framed as a training initiative for higher degree candidates. It will not cover costs for PhD students. Where candidates for a Master’s degree are proposed to work on projects, Lead Applicants must carefully consider:
The complexity, scale, objectives, and dependencies of the project.
The suitability of such project in terms of delivering a clearly identifiable original research project or the potential difficulties in clustering various pieces of work packages for a Master’s thesis. The skills, expertise and experience level required to carry it out.
Any requirements and/or restriction relating to the Master’s candidate’s registration with the Host Institution, and this should be accounted for when determining the start date of the award.
Who can apply?:
Host Institutions from Northern Ireland are not eligible for HRB funding for this call and must instead check their eligibility for funding via the UK funder(s).
Only transnational projects will be funded and consortia must meet specific criteria as detailed in the call text. The partner search tool for this call is available here. Please refer to the OHAMR JTC2027 webpage for all details.
Lead Applicants requesting HRB funding:
Note that HRB use the term ‘Lead Applicant’ to refer to a coordinator or partner applying for HRB funding.
The following will apply to partners seeking HRB funding – i.e., Lead Applicants.[4] If there is more than one Irish partner/coordinator and they are based in different Host Institutions (see below), they must apply as separate partners.
Where more than one Irish coordinator/partner exists, each must meet the Lead Applicant eligibility criteria. However, the HRB will only contract with the Host Institution of one Lead Applicant (this must be the coordinator if an Irish coordinator exists).[5] This Lead Applicant will serve as the primary point of contact for the HRB during the review process and on the award, if successful. They will be responsible for the scientific and technical direction of the Irish research programme. They have primary fiduciary responsibility and accountability for carrying out the research within the funding limits awarded and in accordance with the terms and conditions of the HRB. Where applicable, they must distribute the funds appropriately to the second Irish partner via collaboration and/or consortium agreements.
Each applicant can submit a maximum of two proposals but can only be a coordinator on one.
Lead Applicants must:
Hold a post (permanent or a contract that covers the duration of the award) in a HRB recognised Host Institution in the Republic of Ireland (the “Host Institution”) as an independent investigator. For clinicians, an adjunct position in a HRB recognised Host Institution is acceptable (an accompanying letter of support is required in these cases, as well as in the case of contract positions – see ‘How to apply’ below).
OR
Be an individual who will be recognised by the Host Institution upon receipt of an award as an independent investigator who will have a dedicated office and research space for the duration of award, for which they will be fully responsible. The Lead Applicant does not necessarily need to be employed by the Host Institution at the time of the application submission (an accompanying letter of support is required in these cases – see ‘How to apply’ below).
They must show evidence of achievement as an independent researcher in their chosen research field by:
Demonstrating a record of research output, with at least three publications of original research in peer reviewed journals. Where appropriate, they should also provide evidence of other outputs (e.g., published book chapters, reports to government, research data and datasets, research materials, databases, audio/video products, national and/or international reports, patents, models and protocols, software production, evidence of influence on health policy and practice, outreach and/or knowledge exchange activities, media coverage or other relevant activities) and/or any other relevant outputs that have resulted in a significant impact in their field.
Demonstrating record of independence by showing that they have secured at least one independently peer-reviewed research grant for a research project, as either the Lead Applicant or a Co-Applicant. Funding received for travel to seminars/conferences and/or small personal bursaries will not be considered in this regard.
Show evidence that they possess the capability and authority to manage and supervise the research team.
Partners who are marked in the application as Early Career Researchers should also refer to the section below on Early Career Researchers.
Coordinators are expected to have relevant experience in grant management as Lead Applicant on large awards or as Work Package lead in consortium grants (e.g., Horizon Europe).
Host Institution:
The Host Institution for the award is normally that of the Lead Applicant based in Ireland but it may be another organisation/institution designated by the research team, where it is clearly justified. In order to be eligible to apply for funding, an Institution must be an approved HRB Host Institution no later than two calendar months before the closing date of a call. A list of currently approved HRB Host Institutions can be found on the HRB website.
[4] In view of the overwhelming evidence that both active and passive smoking of tobacco are injurious to health, the HRB is unwilling to fund applications from individuals applying for, holding, or employed under a research grant from the tobacco industry.
[5] For administrative purposes, the second partner will be recorded in HRB systems as a Co-Applicant.
Early Career Researchers::
Early Career Researchers (ECRs) are encouraged to join consortia as full research partners. If you have been marked as an ECR in the application, you must still meet the Lead Applicant criteria above with some additional conditions. These conditions are as follows:
We would require that you have a mentor as a co-applicant on this award to take on joint responsibility of the management of this award.
A letter of support and CV is provided from your Mentor. The letter should acknowledge their role on this application.
Your mentor should be an individual who has strong evidence of:
Leadership experience.
Experience in conducting research projects and programmes.
Track record in scholarly publication and communication (peer-review articles, research data publications, national or international briefing/reports, etc.).
Coaching and mentoring.
The letter should also state that the Mentor will provide support to the Applicant in the management of the grant and any other requisite guidance needed to ensure progress on the deliverables of the research project.
How to apply::
There will be a two-stage application procedure for joint applications. One joint proposal document (in English) shall be prepared by the partners and must be submitted by the Coordinator in electronic format no later than 12:00 GMT on 1 February 2027 via the electronic proposal submission system. No other means of submission will be accepted.
For further details, please refer to the respective submission forms available through the OHAMR JTC2027 webpage. If you need additional information, please contact the Joint Call Secretariat (JCS).
Lead Applicants based in Ireland will be required to provide additional information to the HRB at pre-proposal stage:
All applicants to HRB’s Joint Transnational Calls must demonstrate that they meet the eligibility crit
Documents
- HRB FAQs OHAMR JTC2027
- HRB JTC2027 Budget Guidance
- Expression of Interest Form to attend Brokerage Event (9 December 2026)
- OHAMR JTC2027 webpage
- Webinar registration (25 November 2026, 12:30 - 12:30 GMT))
- Partner search tool
- HRB Lead Applicant eligibility form
- HI JTC sign off form
Change history
First seen 15 Nov 2026, last checked 22 Nov 2026. 4 recorded versions.
- 20 Nov 2026 · 2604508f0fad
- 19 Nov 2026 · 172d04addbf2
- 18 Nov 2026 · 4a4db2d5f07a
- 15 Nov 2026 · fb8ac0b8d545